Switch theme
Sign up to access all valuation multiples
Corestemchemon Inc is a biopharmaceutical company that researches and commercializes stem cell technology. It has developed NEURONATA-R inj., a stem cell therapy for Lou Gehrig's disease which is a rare incurable disease, for the first ALS treatment. Its stem cell therapeutics for Lou Gehrig's disease have a pipeline of incurable diseases such as lupus, multiple system atrophy, and osteoarthritis, and plans to preoccupy the market by focusing on developing therapies for rare incurable diseases based on a development success reference of stem cell therapy for the Lou Gehrig's disease.
2003
n/a
Last FY Revenue $21.1M
Last FY EBITDA -$16.2M
$96.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Corestemchemon achieved revenue of $21.1M and an EBITDA of -$16.2M.
Corestemchemon expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Corestemchemon valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $21.1M | XXX | XXX | XXX |
| Gross Profit | XXX | -$0.8M | XXX | XXX | XXX |
| Gross Margin | XXX | -4% | XXX | XXX | XXX |
| EBITDA | XXX | -$16.2M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -77% | XXX | XXX | XXX |
| EBIT | XXX | -$16.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | -77% | XXX | XXX | XXX |
| Net Profit | XXX | -$19.2M | XXX | XXX | XXX |
| Net Margin | XXX | -91% | XXX | XXX | XXX |
| Net Debt | XXX | $32.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 17, 2025, Corestemchemon's stock price is KRW 3310 (or $2).
Corestemchemon has current market cap of KRW 85.4B (or $62.6M), and EV of KRW 131B (or $96.0M).
See Corestemchemon trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $96.0M | $62.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 17, 2025, Corestemchemon has market cap of $62.6M and EV of $96.0M.
Corestemchemon's trades at 4.6x EV/Revenue multiple, and -5.9x EV/EBITDA.
Equity research analysts estimate Corestemchemon's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Corestemchemon's P/E ratio is not available.
See valuation multiples for Corestemchemon and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $62.6M | XXX | $62.6M | XXX | XXX | XXX |
| EV (current) | $96.0M | XXX | $96.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 4.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -5.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -5.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -3.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCorestemchemon's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Corestemchemon's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Corestemchemon's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Corestemchemon and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -77% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 73% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Corestemchemon acquired XXX companies to date.
Last acquisition by Corestemchemon was XXXXXXXX, XXXXX XXXXX XXXXXX . Corestemchemon acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Corestemchemon founded? | Corestemchemon was founded in 2003. |
| Where is Corestemchemon headquartered? | Corestemchemon is headquartered in South Korea. |
| Is Corestemchemon publicy listed? | Yes, Corestemchemon is a public company listed on KRX. |
| What is the stock symbol of Corestemchemon? | Corestemchemon trades under 166480 ticker. |
| When did Corestemchemon go public? | Corestemchemon went public in 2015. |
| Who are competitors of Corestemchemon? | Similar companies to Corestemchemon include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Corestemchemon? | Corestemchemon's current market cap is $62.6M |
| Is Corestemchemon profitable? | Yes, Corestemchemon is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
